Technical Analysis for XRTX - Xortx Therapeutics Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | -3.08% | |
| Narrow Range Bar | Range Contraction | -3.08% | |
| Doji - Bullish? | Reversal | -3.08% | |
| Wide Bands | Range Expansion | -3.08% | |
| Gapped Down | Weakness | -3.08% | |
| MACD Bullish Signal Line Cross | Bullish | -7.73% | |
| Narrow Range Bar | Range Contraction | -7.73% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 3 days ago |
| Rose Above 10 DMA | 3 days ago |
| Bearish 180 Entry | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| 10 DMA Support | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-05-15
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.35 |
| 52 Week Low | 0.33 |
| Average Volume | 17,470 |
| 200-Day Moving Average | 2.665 |
| 50-Day Moving Average | 4.921 |
| 20-Day Moving Average | 3.837 |
| 10-Day Moving Average | 3.571 |
| Average True Range | 0.302 |
| RSI (14) | 38.27 |
| ADX | 15.75 |
| +DI | 27.839 |
| -DI | 30.331 |
| Chandelier Exit (Long, 3 ATRs) | 4.045 |
| Chandelier Exit (Short, 3 ATRs) | 4.305 |
| Upper Bollinger Bands | 4.475 |
| Lower Bollinger Band | 3.199 |
| Percent B (%b) | 0.2 |
| BandWidth | 33.234 |
| MACD Line | -0.328 |
| MACD Signal Line | -0.344 |
| MACD Histogram | 0.0163 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.685 | ||||
| Resistance 3 (R3) | 3.710 | 3.660 | 3.648 | ||
| Resistance 2 (R2) | 3.660 | 3.603 | 3.648 | 3.635 | |
| Resistance 1 (R1) | 3.560 | 3.567 | 3.535 | 3.535 | 3.622 |
| Pivot Point | 3.510 | 3.510 | 3.498 | 3.498 | 3.510 |
| Support 1 (S1) | 3.410 | 3.453 | 3.385 | 3.385 | 3.298 |
| Support 2 (S2) | 3.360 | 3.417 | 3.348 | 3.285 | |
| Support 3 (S3) | 3.260 | 3.360 | 3.273 | ||
| Support 4 (S4) | 3.235 |
